Evidence map›Paper›PMID 30689732›Full record

ArticleBioinformatics (Oxford, England)2019

DeepAMR for predicting co-occurrent resistance of Mycobacterium tuberculosis.

Yang Yang, Timothy M Walker, A Sarah Walker, Daniel J Wilson, Timothy E A Peto, Derrick W Crook, Farah Shamout, CRyPTIC Consortium, Tingting Zhu, David A Clifton

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Future Research Directions on Mycobacterium tuberculosis Proteins.Advances in experimental medicine and biology · 2026
    Review
  6. Article
  7. Review
  8. Predicting rifampicin resistance inERJ open research · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Prediction of pyrazinamide resistance inJAC-antimicrobial resistance · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yang YangInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Timothy M WalkerNuffield Department of Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Oxford, UK.
A Sarah WalkerNuffield Department of Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Oxford, UK.
Daniel J WilsonBig Data Institute, Nuffield Department of Population Health, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Old Road Campus, Oxford, UK.
Timothy E A PetoNuffield Department of Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Oxford, UK.
Derrick W CrookNuffield Department of Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Oxford, UK.
Farah ShamoutInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
CRyPTIC Consortium
Tingting ZhuInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
David A CliftonInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.

Funding

New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosisK01ES026835 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · PI FARHAT, MAHA · 2015 to 2019
$1.1M
Department of HealthMedical Research Council MC_PC_16027NIEHS NIH HHS K01 ES026835Wellcome Trust 101237/Z/13/ZWellcome Trust 200205/Z/15/Z
6 · The paper itself

Abstract

motivationResistance co-occurrence within first-line anti-tuberculosis (TB) drugs is a common phenomenon. Existing methods based on genetic data analysis of Mycobacterium tuberculosis (MTB) have been able to predict resistance of MTB to individual drugs, but have not considered the resistance co-occurrence and cannot capture latent structure of genomic data that corresponds to lineages.

resultsWe used a large cohort of TB patients from 16 countries across six continents where whole-genome sequences for each isolate and associated phenotype to anti-TB drugs were obtained using drug susceptibility testing recommended by the World Health Organization. We then proposed an end-to-end multi-task model with deep denoising auto-encoder (DeepAMR) for multiple drug classification and developed DeepAMR_cluster, a clustering variant based on DeepAMR, for learning clusters in latent space of the data. The results showed that DeepAMR outperformed baseline model and four machine learning models with mean AUROC from 94.4% to 98.7% for predicting resistance to four first-line drugs [i.e. isoniazid (INH), ethambutol (EMB), rifampicin (RIF), pyrazinamide (PZA)], multi-drug resistant TB (MDR-TB) and pan-susceptible TB (PANS-TB: MTB that is susceptible to all four first-line anti-TB drugs). In the case of INH, EMB, PZA and MDR-TB, DeepAMR achieved its best mean sensitivity of 94.3%, 91.5%, 87.3% and 96.3%, respectively. While in the case of RIF and PANS-TB, it generated 94.2% and 92.2% sensitivity, which were lower than baseline model by 0.7% and 1.9%, respectively. t-SNE visualization shows that DeepAMR_cluster captures lineage-related clusters in the latent space. AVAILABILITY AND IMPLEMENTATION: The details of source code are provided at http://www.robots.ox.ac.uk/∼davidc/code.php. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Mycobacterium tuberculosisAntitubercular AgentsMicrobial Sensitivity TestsPyrazinamideAntitubercular AgentsPyrazinamide

Identifiers

PMID30689732
PMCPMC6748723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.